Department of Integrated Traditional Chinese and Western Medicine, Shanghai First Maternity and Infant Hospital, Tongji University, Shanghai, 200040, China.
Prenatal Diagnosis Center, Shanghai First Maternity and Infant Hospital, Tongji University, Shanghai, 200040, China.
J Ovarian Res. 2024 Feb 14;17(1):40. doi: 10.1186/s13048-024-01363-x.
Poor ovarian response (POR) is a big challenge for in vitro fertilization. The traditional Chinese medicine, Cai's Prescription of Tonifying Kidney and Strengthening Vitals (Cai's Prescription) has yielded satisfactory results for POR treatment clinically, but systematic scientific research of Cai's Prescription is not well reported. This study aimed to investigate the clinical effect of Cai's Prescription on poor ovarian responders and its biological mechanism.
Serum was collected from poor ovarian responders, and IL-1β, INFγ, FSH, E and AMH levels were analyzed by ELISA. Ovarian antral follicles were identified and counted using transvaginal ultrasound. The embryo quality grading were done on day 3 after retrieval. We used high-throughput sequencing of granulosa cells to investigate the gene transcription patterns of ovarian granulosa cells in poor ovarian responders after Cai's Prescription pretreatment. The expression level of ARHGAP4 was analyzed by quantitative real-time PCR and western blot. The effects of ARHGAP4 for granulosa cells were analyzed by CCK-8 assay, annexin-V and PI staining, ELISA and western blot. The effects of Cai's Prescription on the expression of PI3K-Akt pathway and apoptosis were analyzed by western blot.
In this study, we found that Cai's Prescription pretreatment had the tendency to improve the ovarian reserve function and could increase the number of high quality embryos for poor ovarian responders. Through high-throughput sequencing of mRNA in granulosa cells, we discovered ARHGAP4, which is a member of GTPase-activating proteins (GAPs) may be a candidate target for POR treatment. ARHGAP4 was significantly increased in poor ovarian responders and can be recovered after Cai's Prescription pretreatment. Mechanically, combining the cell line model and clinical tissue samples, we found that ARHGAP4 can accelerate cell apoptosis and inflammation response in granulosa cells via PI3K-Akt signaling pathway. In addition, Cai's Prescription pretreatment for three months significantly reduced the high level of ARHGAP4 in poor ovarian responders.
This study shows that the traditional Chinese medicine, Cai's Prescription yielded satisfactory results for poor ovarian responders clinically and ARHGAP4 may be a candidate target for POR treatment.
卵巢反应不良(POR)是体外受精的一大挑战。中药补肾填精方(Cai's Prescription)在临床上对 POR 治疗有满意的效果,但系统的科学研究报道并不多。本研究旨在探讨补肾填精方对 POR 患者的临床疗效及其生物学机制。
收集 POR 患者的血清,采用 ELISA 法检测 IL-1β、INFγ、FSH、E 和 AMH 水平。经阴道超声鉴定和计数卵巢窦卵泡。取卵后第 3 天进行胚胎质量分级。我们使用高通量测序技术研究补肾填精方预处理后 POR 患者卵巢颗粒细胞的基因转录模式。采用定量实时 PCR 和 Western blot 分析 ARHGAP4 的表达水平。通过 CCK-8 检测、Annexin-V 和 PI 染色、ELISA 和 Western blot 分析 ARHGAP4 对颗粒细胞的影响。通过 Western blot 分析补肾填精方对 PI3K-Akt 通路和凋亡的影响。
本研究发现,补肾填精方预处理有改善卵巢储备功能的趋势,可增加 POR 患者的优质胚胎数。通过对颗粒细胞 mRNA 的高通量测序,我们发现 ARHGAP4 可能是 POR 治疗的候选靶点,它是 GTPase-activating proteins (GAPs) 的一个成员。在 POR 患者中,ARHGAP4 显著增加,经补肾填精方预处理后可恢复。从细胞系模型和临床组织样本两方面来看,我们发现 ARHGAP4 可以通过 PI3K-Akt 信号通路加速颗粒细胞的凋亡和炎症反应。此外,补肾填精方预处理 3 个月可显著降低 POR 患者中高水平的 ARHGAP4。
本研究表明,中药补肾填精方在临床上对 POR 患者有满意的效果,ARHGAP4 可能是 POR 治疗的候选靶点。